1-2 of 2
Jan Novak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

Open Access
Clinical Trials & Observations
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Karim Laribi, Vladimir Ivanov, MD, Inho Kim, Jan Novak, Rebecca Champion, Walter Fiedler, Maria Pagoni, Julie Bergeron, MD, Stephen B Ting, Jing-Zhou Hou, Hematology Oncology, Takahiro Yamauchi, Jianxiang Wang, Stephen A. Strickland, Michael R. Savona, Tara L. Lin, Anoop K. Enjeti, Ing Soo Tiong, Sangmin Lee, Gail J Roboz, Relja Popovic, Qi Jiang, Zihuan Liu, Yan Sun, Wellington L Mendes, Brenda Chyla, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv bloodadvances.2025017083.
https://doi.org/10.1182/bloodadvances.2025017083
Published: 2025
Includes: Supplemental data
Journal Articles

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Free
Clinical Trials & Observations
Pierre Fenaux, Marco Gobbi, Patricia L. Kropf, Jean-Pierre J. Issa, Gail J. Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw. W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph Brandwein, Liana Gercheva-Kyuchukova, Judit Demeter, Elizabeth Griffiths, Karen Yee, Konstanze Döhner, Yong Hao, Harold Keer, Mohammad Azab, Hartmut Döhner
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5027–5037.
https://doi.org/10.1182/bloodadvances.2023010179
Published: 2023
Includes: Supplemental data